Mean CSF analyte concentrations
| Variable | NC | AD1 | AD2 | PSP |
|---|---|---|---|---|
| AlzBio3 Aβ42 (pg/mL) | 348.1±75.7 | 237.5±82.7* | 167.06±73.49†,‡ | 269.0±87.0§ |
| AlzBio3 total τ (pg/mL) | 79.0±33.1¶ | 138.4±88.6 | 111.09±78.17 | 55.9±20.1§,**,†† |
| AlzBio3 ptau (pg/mL) | 29.1±9.4¶,‡‡ | 44.7±25.7 | 50.47±33.15 | 22.1±7.4§,**,†† |
| Tau12-BT2 (pg/mL) | 773.3±275.8¶,‡‡ | 1312.4±591.5 | 1180.03±774.95 | 549.3±173.9§,**,†† |
| BT2-HT7 (pg/mL) | 1587.2±652.9¶,‡‡ | 2719.4±1630.1 | 2786.06±2079.67 | 1205.6±390.2§,**,†† |
| HT7-Tau5 (pg/mL) | 639.7±300.1¶,‡‡ | 1442.1±909.6 | 1353.13±989.99 | 546.2±186.5**,†† |
| HT7-PTau181 (pg/mL) | 64.0±17.4¶,‡‡ | 96.4±42.1 | 82.06±42.49 | 51.7±17.5§,**,†† |
| Tau12-HT7 (pg/mL) | 409.9±141.9¶,‡‡ | 788.2±414.0 | 789.08±603.01 | 321.5±117.7**,†† |
Group differences in CSF AlzBio3 and CSF τ assays. CSF levels are displayed by means and SDs within each group.
*AD1<NC (p<0.05).
†AD2<NC (p<0.05).
‡AD2<PSP (p<0.05).
§PSP<NC (p<0.05).
¶NC<AD1 (p<0.05).
**PSP<AD1 (p<0.05).
††PSP<AD2 (p<0.05).
‡‡NC<AD2 (p<0.05).
AD1, Alzheimer's disease in the original cohort; AD2, Alzheimer's disease in the second cohort; NC, normal control; PSP, progressive supranuclear palsy.